Administration of acemannan

Details Administration of acemannan Administration of acemannan

1988-08-05

1992-04-21

Rollins, John W.

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

514 54, 514885, A61K 4505, A61K 31715

Patent

active

051066165

ABSTRACT:
Acemannan has now been discovered to be a potent inducer of Interleukin 1 (Il-1) and prostaglandin E.sub.2 (PGE.sub.2) production by human peripheral blood adherent cells in culture. Il-1 has been shown to be an important macrophage product and is associated with influencing the activity and production of T lymphocytes, fibroblasts, B lymphocytes and endothelial cells. Acemannan has no demonstrated toxicity, and acts as an adjuvant and immunoenhancer. Administration of an amount of acemannan sufficient to stimulate monocytes and macrophages not only produces Il-1 and PGE.sub.2 but also stimulates phagocytosis, increases antibody production, enhances antiviral activity in the serum and, in those patients with AIDS/ARC, produces defective HIV virus.
Acemannan has been shown to affect the rate of virus production in viral vaccine master seed cultures by accelerating the rate of viral replication. In addition, acemannan is a potent adjuvant to viral vaccines in chickens. Acemannan has also shown specific antitumor activity against sarcoid tumors in horses.

REFERENCES:
patent: 4555987 (1985-12-01), Tumlinson
Gowda et al., "Structural Studies of Polysaccharides From Aloe vera," Carbohy. Res. 72:201-205, 1979.

Affiliated with

Also associated with

Rating

Administration of acemannan does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Administration of acemannan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of acemannan will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1584865